

1 **Supporting information for**

2 **PI3K block restores age-dependent neurovascular coupling defects**  
3 **associated with cerebral small vessel disease**

4 Pratish Thakore<sup>1†</sup>, Evan Yamasaki<sup>1†</sup>, Sher Ali<sup>1†</sup>, Alfredo Sanchez Solano<sup>1</sup>, Cassandre  
5 Labelle-Dumais<sup>2</sup>, Xiao Gao<sup>3,4</sup>, Myriam M. Chaumeil<sup>3,4</sup>, Douglas B. Gould<sup>2</sup>, and Scott  
6 Earley<sup>1\*</sup>

7 <sup>1</sup>Department of Pharmacology, Center for Molecular and Cellular Signaling in the  
8 Cardiovascular System University of Nevada, Reno School of Medicine; Reno, Nevada,  
9 89557-0318, USA

10 <sup>2</sup>Department of Ophthalmology and Anatomy, Institute for Human Genetics, University  
11 of California San Francisco School of Medicine; San Francisco, CA 94143, USA

12 <sup>3</sup>Department of Physical Therapy and Rehabilitation Science, UCSF, San Francisco  
13 USA


14 <sup>4</sup>Department of Radiology and Biomedical Imaging, UCSF, San Francisco USA

15 **\*Corresponding author:** Email: [searley@med.unr.edu](mailto:searley@med.unr.edu)

16 †These authors contributed equally to this work.

17 **\*Address Correspondence To:** Scott Earley, Ph.D.  
18 University of Nevada, Reno School of Medicine  
19 Manville Health Sciences Building, Room 8  
20 MS-0318  
21 Reno, NV, 89557-0318, USA  
22 Phone: (775) 784-4117  
23 Fax: (775) 784-1620  
24 Email: [searley@med.unr.edu](mailto:searley@med.unr.edu)

25 Supplemental figures




26


27 **Fig. S1 – supplement 1. Kir2.1 currents in cerebral artery ECs.** (A) Illustration of the  
 28 cerebral artery EC isolation procedure. Scale bar = 10 μm. (B) Representative I-V  
 29 traces and summary data showing Kir2.1 current densities in freshly isolated cerebral  
 30 artery ECs from 3 M-old *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice (n = 5–6 cells from 5 animals  
 31 per group, ns = not significant, unpaired t-test). (C) Representative I-V traces and  
 32 summary data showing Kir2.1 current densities in freshly isolated cerebral artery ECs  
 33 from 12 M-old *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice (n = 6–10 cells from 3 to 4 animals per

34 group; \* $p < 0.05$ , unpaired t-test). (D and E) Representative traces (D) and summary data  
35 (E) demonstrating the vasodilator response to raising extracellular [K<sup>+</sup>] in cerebral  
36 arteries from 12 M-old *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice (n = 9–13 preparations from 6  
37 to 10 animals per group, \* $p < 0.05$ , non-repeated measures two-way ANOVA). (F)  
38 Summary data showing the contractile response to 30 and 60 mM [K<sup>+</sup>] in cerebral  
39 arteries from 12 M-old *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice (n = 7–12 preparations from 5  
40 to 10 animals per group, ns = not significant, unpaired t-test).

A




B



41

42 **Fig. S2 – supplement 2. High field magnetic resonance imaging.** (A) Representative  
 43 susceptibility weighted (SWI) and T2 weighted (T2W) MRI images from 12 M-old  
 44 *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice. (B) Quantification of ventricle/brain ratio for 12 M-old  
 45 *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice (n = 7 animals per group, ns = not significant, unpaired  
 46 t-test).



47

48 **Fig. S3 – supplement 1. Functional hyperemic response following 2 and 20 s**

49 **whisker stimulation.** (A and B) Representative traces (A) and summary data (B)

50 showing the increase in blood flow following 2 s contralateral whisker stimulation (WS)

51 in 3 M-old *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice (n = 6 animals per group, ns = not

52 significant, unpaired t-test). (C to F) Latency (C), duration (D), rise rate (E) and decay

53 rate (F) were also analyzed (n= 6 animals per group, ns = not significant, unpaired t-

54 test). (G and H) Representative traces (G) and summary data (H) showing the increase


55 in blood flow following 2 s contralateral WS in 12 M-old *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice

56 (n = 6 animals per group, \*p<0.05, unpaired t-test). (I to L) Latency (I), duration (J), rise

57 rate (K) and decay rate (L) were also analyzed (n = 6 animals per group, \*p<0.05, ns =

58 not significant, unpaired t-test). (M and N) Representative traces (M) and summary data

- 59 (N) the increase in blood flow following 20 s contralateral WS in 12 M-old *Col4a1*<sup>+/+</sup> and
- 60 *Col4a1*<sup>+/*G394V*</sup> mice (n = 5 animals per group, \*p<0.05, unpaired t-test).




61

62 **Fig. S3 – supplement 2. Ipsilateral whisker stimulation.** (A to C) Summary data  
 63 showing no change in blood flow following ipsilateral whisker stimulation for 1 s (A), 2 s  
 64 (B), and 5 s (C) in 3 M- and 12 M-old *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice (n = 6 animals  
 65 per group, ns = not significant, unpaired t-test). (D) Summary data showing no change

- 66 in blood flow following ipsilateral whisker stimulation for 20 s in 12 M-old *Col4a1<sup>+/+</sup>* and
- 67 *Col4a1<sup>+G394V</sup>* mice (n = 5 animals per group, ns = not significant, unpaired t-test).





68

69 **Fig. S3 – supplement 3. Whisker stimulation response in the presence of BaCl<sub>2</sub>.** (A

70 and B) Representative traces (A) and summary data (B) showing the increase in blood

71 flow following 1 s contralateral whisker stimulation (WS) in 12 M-old *Col4a1*<sup>+/+</sup> and

72 *Col4a1*<sup>+/G394V</sup> mice before and after topical BaCl<sub>2</sub> (100 μM) application to the cranial

73 surface (n = 5 animals per group, \*p<0.05, ns = not significant, repeated measures two-

74 way ANOVA). (C to F) Latency (C), duration (D), rise rate (E) and decay rate (F) were

75 also analyzed (n= 5 animals per group, \*p<0.05, ns = not significant, repeated

76 measures two-way ANOVA). (G) No change in blood flow was detected following 1 s

77 ipsilateral whisker stimulation (n= 5 animals per group, \*p<0.05, ns = not significant,

78 repeated measures two-way ANOVA). (H and I) Representative traces (H) and


79 summary data (I) showing the increase in blood flow following 2 s contralateral whisker

80 stimulation (WS) in 12 M-old *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice before and after topical

81 BaCl<sub>2</sub> (100 μM) application to the cranial surface (n = 5 animals per group, \*p<0.05, ns


82 = not significant, repeated measures two-way ANOVA). (J to M) Latency (J), duration

83 (K), rise rate (L) and decay rate (M) were also analyzed (n= 5 animals per group,  
84 \*p<0.05, ns = not significant, repeated measures two-way ANOVA). (N) No change in  
85 blood flow was detected following 2 s ipsilateral whisker stimulation (n= 5 animals per  
86 group, \*p<0.05, ns = not significant, repeated measures two-way ANOVA). (O and P)  
87 Representative traces (O) and summary data (P) showing the increase in blood flow  
88 following 5 s contralateral whisker stimulation (WS) in 12 M-old *Col4a1<sup>+/+</sup>* and  
89 *Col4a1<sup>+/G394V</sup>* mice before and after topical BaCl<sub>2</sub> (100 μM) application to the cranial  
90 surface (n = 5 animals per group, \*p<0.05, ns = not significant, repeated measures two-  
91 way ANOVA). (Q to T) Latency (Q), duration (R), rise rate (S) and decay rate (T) were  
92 also analyzed (n= 5 animals per group, \*p<0.05, ns = not significant, repeated  
93 measures two-way ANOVA). (U) No change in blood flow was detected following 5 s  
94 ipsilateral whisker stimulation (n= 5 animals per group, \*p<0.05, ns = not significant,  
95 repeated measures two-way ANOVA).



96

97 **Fig. S3 – supplement 4. Cerebral blood flow response to application of KCl to the**  
 98 **cranial surface.** (A and B) Representative traces (A) and summary data (B) showing  
 99 the increase in blood flow in 12 M-old *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/*G394V*</sup> mice following topical  
 100 application of KCl (10 mM) onto the cranial surface, in the absence and presence of  
 101 BaCl<sub>2</sub> (100 μM) (n= 5 animals per group, \*p<0.05, ns = not significant, repeated  
 102 measures two-way ANOVA).



103

104 **Fig. S4 – supplement 1. ATP levels in brain capillary ECs.** (A) PIP<sub>2</sub> synthesis

105 pathway. (B) Summary data showing normalized [ATP] in brain capillary ECs from 12

106 M-old *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice. (n = 9 sets of ~500 cells from three mice per

107 group, ns = not significant, unpaired t-test). (C) PIP<sub>2</sub> depletion pathway. (D)


108 Representative I-V traces and summary data showing Kir2.1 current densities in freshly

109 isolated brain capillary ECs treated with the PLC inhibitor U73122 (10 μM) from 12 M-

110 old *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice (n = 4 cells from 3 animals per group, \*p<0.05,

111 unpaired t-test).

112



113

114 **Fig. S4 – supplement 2. GSK1059615 vehicle and SNP response. (A and B)**

115 Representative trace (A) and summary data (B) showing K<sup>+</sup> (10 mM, blue box)-induced

116 dilation of upstream arterioles in preparations before and after superfusing the vehicle

117 (0.01% v/v DMSO, 30 min) from 12 M-old *Col4a1*<sup>+/+</sup> mice (n = 6 preparations from 4

118 animals per group, ns = not significant, paired t-test). (C and D) Representative trace

119 (C) and summary data (D) showing K<sup>+</sup> (10 mM, blue box)-induced dilation of upstream

120 arterioles in preparations before and after superfusing the vehicle (0.01% v/v DMSO, 30


121 min) from 12 M-old *Col4a1*<sup>+/G394V</sup> mice (n = 6 preparations from 4 animals per group, ns

122 = not significant, paired t-test). (E and F) Summary data showing that the dilation

123 produced by superfusing SNP (10 μM) in the presence of GSK1059615 (10 nM, 30 min)

124 (E), and vehicle (0.01% v/v DMSO, 30 min) (F) in preparations from 12 M-old *Col4a1*<sup>+/+</sup>

125 and *Col4a1*<sup>+/*G394V*</sup> mice (n = 6 preparations from 3 to 5 animals per group, ns = not  
126 significant, unpaired t-test).



127

128 **Fig. S5 – supplement 1. Functional hyperemic response following 2 s and 5 s**

129 **whisker stimulation in GSK1059615-treated animals.** (A and B) Representative

130 traces (A) and summary data (B) showing the increase in blood flow following 2 s

131 contralateral whisker stimulation (WS) in 12 M-old *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice

132 treated with vehicle (saline) or GSK1059615 (10 mg/kg) for 28 days, s.c. (n = 5 animals

133 per group, \*p<0.05, ns = not significant, non-repeated measures two-way ANOVA). (C

134 to F) Latency (C), duration (D), rise rate (E) and decay rate (F) were also analyzed (n= 5

135 animals per group, \*p<0.05, ns = not significant, non-repeated measures two-way

136 ANOVA). (G and H) Representative traces (G) and summary data (H) showing the

137 increase in blood flow following 5 s contralateral WS in 12 M-old *Col4a1*<sup>+/+</sup> and


138 *Col4a1*<sup>+/G394V</sup> mice treated with vehicle (saline) or GSK1059615 (10 mg/kg) for 28 days,

139 s.c. (n = 5 animals per group, \*p<0.05, ns = not significant, non-repeated measures two-

140 way ANOVA). (I to L) Latency (I), duration (J), rise rate (K) and decay rate (L) were also

141 analyzed (n= 5 animals per group, \*p<0.05, ns = not significant, non-repeated measures


142 two-way ANOVA).



143

144 **Fig. S5 – supplement 2. Ipsilateral whisker stimulation in GSK1059615 treated**  
 145 **animals.** (A to C) Summary data showing no change in blood flow following ipsilateral  
 146 whisker stimulation for 1 s (A), 2 s (B), and 5 s (C) in 12 M-old *Col4a1*<sup>+/+</sup> and  
 147 *Col4a1*<sup>+/G394V</sup> mice treated with vehicle (saline) or GSK1059615 (10 mg/kg) for 28 days,  
 148 s.c. (n = 5 animals per group, ns = not significant, non-repeated measures two-way  
 149 ANOVA).





150

151 **Fig. S5 – supplement 3. Myogenic response in GSK1059615 treated animals. (A)**

152 Typical recordings of the inner diameter of isolated cerebral arteries from 12 M-old

153 *Col4a1*<sup>+/+</sup> and *Col4a1*<sup>+/G394V</sup> mice treated with GSK1059615 (10 mg/kg) for 28 days

154 showing the myogenic response to increases in intraluminal pressure (active) and the

155 dilation of the same arteries when extracellular Ca<sup>2+</sup> has been removed (passive). (B)

156 Summary data showing the effects of GSK1059615 treatment on myogenic tone (n= 5

157 preparations from 3 animals per group, ns = not significant, repeated measures two-way

158 ANOVA).